Combined IL-24 and WP1066 treatment elicited more pronounced growth suppression in both MDA-MB-231 and HCC-1954 cells than WP1066 treatment alone (Fig. 6G, H), suggesting that IL-24 may sensitize breast cancer cells to WP1066. The gene discussed is IL24; the disease is breast carcinoma.